Doximity (DOCS) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual Meeting scheduled for August 28, 2025, to be held virtually, with voting available online, by phone, mail, or during the meeting.
Record date for voting eligibility is July 3, 2025; both Class A and Class B common stockholders may vote as a single class.
Proposals include election of two Class I directors, ratification of Deloitte & Touche LLP as auditor, and a non-binding advisory vote on executive compensation.
Board recommends voting FOR all proposals.
Voting matters and shareholder proposals
Election of Jeff Tangney and Kira Wampler as Class I directors for a term ending in 2028.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending March 31, 2026.
Advisory vote on executive compensation (Say-on-Pay) for fiscal year 2025.
Shareholders may submit proposals for the 2026 meeting by March 18, 2026, and director nominations by April 17, 2026.
Board of directors and corporate governance
Board is divided into three staggered classes; majority are independent per NYSE standards.
CEO serves as board chair, facilitating unified leadership.
Board committees: audit, compensation, and nominating/governance, all comprised of independent directors.
Annual board and committee self-evaluations; code of conduct and whistleblower procedures in place.
Latest events from Doximity
- All proposals passed, electing directors through 2029 and confirming Deloitte as auditor.DOCS
AGM 2026 - Revenue up 7% to $157M, net income down, strong AI adoption, over $90M in share repurchases.DOCS
Q1 2027 - Leading U.S. physician network leverages AI and workflow tools for strong growth and profitability.DOCS
Investor presentation - Proxy covers director elections, auditor ratification, and executive pay, with strong governance and ESG focus.DOCS
Proxy filing - Virtual meeting to vote on directors, auditor, and executive pay, with board support for all.DOCS
Proxy filing - Delivers AI-powered workflow tools to 85%+ of U.S. physicians, achieving 22% revenue CAGR.DOCS
Investor presentation - Record free cash flow, strong AI adoption, and 13% revenue growth set up modest FY27 outlook.DOCS
Q4 2026 - Revenue up 10% to $185.1M, strong margins, AI acquisition, and $500M buyback authorized.DOCS
Q3 2026 - 20% revenue growth, record margins, and strong AI-driven engagement set up for cautious FY26.DOCS
Q4 2025 - Q3 revenue up 25% with margin expansion, record engagement, and ongoing share repurchases.DOCS
Q3 2025